The evolving role of antifungal susceptibility testing

Pharmacotherapy

Volumn 33, Issue 5, 2013, Pages 465-475

  Eschenauer, Gregory A ^a   Carver, Peggy L ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antifungal susceptibility testing; Antifungals; Azole antifungal; Clinical breakpoints; Echinocandin; Epidemiological cut off value; Fluconazole; Resistance

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIFUNGAL SUSCEPTIBILITY TESTING; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DRUG EFFICACY; HUMAN; INVASIVE CANDIDIASIS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; SYSTEMIC MYCOSIS; WILD TYPE;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; PRACTICE GUIDELINES AS TOPIC;

EID: 84879575734     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1233     Document Type: Article

References (61)

1. Pai MP, Pendland SL. Antifungal susceptibility testing in teaching hospitals. Ann Pharmacother 2003;37(2):192-196.
2. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006;19:435-447.
3. Collins CD, Eschenauer GA, Salo SL, Newton DW. To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemia. J Clin Microbiol 2007;45:1884-1888.
4. Lass-Florl C, Perkhofer S, Mayr A. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses 2010;53:1-11.
5. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997;24:235-247.
6. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002;35(8):982-989.
7. Kahlmeter G, Brown DF, Goldstein FW, et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 2003;52(2):145-148.
8. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010;13:180-195.
9. Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011;70:330-343.
10. Kahlmeter G, Brown DFJ. Harmonization of Antimicrobial breakpoints in Europe - Can it be achieved? Clin Microbiol Newsl 2004;26:187-192.
11. Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007;20(3):391-408.
12. Arendrup MC, Kahlmeter G, Rodriguez-Tudela JL, Donnelly JP. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob Agents Chemother 2009;53(4):1628-1629.
13. Turnidge J, Kahlmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006;12(5):418-425.
14. Pfaller MA, Espinel-Ingroff A, Canton E, et al. Wild-type MIC distributions and epidemiological cutoff values for Amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012;50 (6):2040-2046.
15. Simjee S, Silley P, Werling HO, Bywater R. Potential confusion regarding the term "resistance" in epidemiological surveys. J Antimicrob Chemother 2008;61(1):228-229.
16. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999;43:2116-2120.
17. Louie A, Liu QF, Drusano GL, et al. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob Agents Chemother 1998;42(6):1512-1514.
18. Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D, et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007;51: 3599-3604.
19. Lee SC, Fung CP, Huang JS, et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000;44:2715-2718.
20. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus Amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995;39:40-44.
21. Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005;49:3171-3177.
22. Pai M, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007;51:35-39.
23. Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008;52:3022-3028.
24. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur J Clin Microbiol Infect Dis 2004;23:380-388.
25. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Informational supplement M27-A3. Wayne, PA: Clinical Laboratory Standards Institute Clinical Laboratory Standards Institute; 2008.
26. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011;14:164-176.
27. Pappas PF, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis 2009;48:503-535.
28. European Committee on Antimicrobial Susceptibility Testing. Voriconazole: rationale for the clinical breakpoints, version 2.0, 2010. Available from http://www.eucast.org. Accessed June 14, 2012.
29. Pfaller MA, Castenheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012;50:1199-1203.
30. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011;55:4782-4788.
31. Powderly WG, Kobayashi GS, Herzig GP, Medoff F. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988;84:826-832.
32. Nguyen MH, Clancy CJ, Yu VL, et al. Do in vitro susceptibility data predict the microbiologic response to Amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998;177:425-430.
33. Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with Amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother 1999;43:1289- 1290.
34. Park BJ, Arthington-Skaggs BA, Hajjeh RA, et al. Evaluation of Amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 2006;50:1287-1292.
35. Arendrup MC, Pfaller MA; the Danish Fungaemia Study Group. Caspofungin etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised caspofungin CLSI breakpoints. Antimicrob Agents Chemother 2012;56 (7):3965-3968.
36. Spreghini E, Orlando F, Sanguinetti M, et al. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata. Antimicrob Agents Chemother 2012;56(3):1215-1222.
37. Arendrup MC, Garcia-Effron G, Buzina W, et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 2009;53(3):1185-1193.
38. Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, et al. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Chemother 2011;55:3075-3083.
39. Wiederhold NP, Najvar LK, Bocanegra RA, Kirkpatrick WR, Patterson TF. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother 2011;55:3254-3260.
40. Shields RK, Nguyen MH, Press EG, et al. The presence of an FKS mutation rather than MIC Is an independent risk factor for failure of Echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 2012;56:4862-4869.
41. Kartsonis N, Killar J, Mixson L, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005;49:3616-3623.
42. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-2029.
43. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagn Microbiol Infect Dis 2011;71:252-259.
44. Lockhart SR, Iqbal N, Bolden CB, et al. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis 2012;73(2):144-148.
45. Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for Amphotericin B and flucytosine. Antimicrob Agents Chemother 2012;56 (6):3107-3113.
46. Aller AI, Martin-Mazuelos E, Lozano F, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000;44:1544-1548.
47. Bicanic T. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006;43:1069-1073.
48. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50:291-322.
49. Larsen RA, Bauer M, Pitisuttithum P, et al. Correlation of susceptibility of Cryptococcus neoformans to Amphotericin B with clinical outcome. Antmicrob Agents Chemother 2011;55:5624-5630.
50. Verweij PE, Howard SJ, Melchers WJG, Denning DW. Azoleresistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009;12:141-147.
51. Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008;21:157-197.
52. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007;20:695-704.
53. Verweij PE, Mellado E, Melchers WJG. Multiple-triazole-resistant Aspergillosis. N Engl J Med 2007;356:1481-1483.
54. Baddley JW, Marr KA, Andes DR, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the transplant-associated infection surveillance network. J Clin Microbiol 2009;47:3271-3275.
55. Pfaller M, Boyken L, Hollis R, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J Clin Microbiol 2011;49:586-590.
56. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009;15(7):1068-1076.
57. Arendrup MC, Perkhofer S, Howard SJ, et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 2008;52:3504-3511.
58. Espinel-Ingroff A, Fothergill A, Fuller J, Johnson E, Pelaez T, Turnidge J. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 Document). Antimicrob Agents Chemother 2011;55:2855-2859.
59. Lockhart SR, Zimbeck AJ, Baddley JW, et al. In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the transplant-associated infection surveillance network. Antimicrob Agents Chemother 2011;55:3944-3946.
60. Carver PL, Dang K, Dekarske BM, Rudoni MA, Rutherford D, Zechmeister C. Evaluation of a unit-specific vs hospital-wide fungal antibiogram for Candida species. 17th Symposium on Infections in the Immunocompromised Host (ICHS) Meeting. Genoa, Italy. June 2012.
61. Shah DN, Yau R, Weston J, et al. Evaluation of antifungal therapy in patients with candidemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother 2011;66:2146-2151.